Use	O
of	O
Platelet	B:C0032184
Function	I:C0032184
Testing	I:C0032184
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	O
:	O
A	O
Multicenter	O
Cohort	O
Study	O
Thromboembolic	O
complications	O
constitute	O
a	O
significant	O
source	O
of	O
morbidity	O
after	O
neurointerventional	O
procedures	I:C0184661
.	O

Use	O
of	O
Platelet	O
Function	I:C0032184
Testing	I:C0032184
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	B:C1533810
:	O
A	O
Multicenter	O
Cohort	O
Study	O
Thromboembolic	O
complications	O
constitute	O
a	O
significant	O
source	O
of	O
morbidity	O
after	O
neurointerventional	O
procedures	I:C0184661
.	O

Use	O
of	O
Platelet	O
Function	I:C0032184
Testing	I:C0032184
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	O
:	O
A	O
Multicenter	B:C1096776
Cohort	O
Study	O
Thromboembolic	O
complications	O
constitute	O
a	O
significant	O
source	O
of	O
morbidity	O
after	O
neurointerventional	O
procedures	I:C0184661
.	O

Use	O
of	O
Platelet	O
Function	I:C0032184
Testing	I:C0032184
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	O
:	O
A	O
Multicenter	O
Cohort	O
Study	O
Thromboembolic	O
complications	B:C0009566
constitute	O
a	O
significant	O
source	O
of	O
morbidity	O
after	O
neurointerventional	O
procedures	I:C0184661
.	O

Use	O
of	O
Platelet	O
Function	I:C0032184
Testing	I:C0032184
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	O
:	O
A	O
Multicenter	O
Cohort	O
Study	O
Thromboembolic	O
complications	O
constitute	O
a	O
significant	O
source	B:C0449416
of	O
morbidity	O
after	O
neurointerventional	O
procedures	I:C0184661
.	O

Use	O
of	O
Platelet	O
Function	I:C0032184
Testing	I:C0032184
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	O
:	O
A	O
Multicenter	O
Cohort	O
Study	O
Thromboembolic	O
complications	O
constitute	O
a	O
significant	O
source	O
of	O
morbidity	O
after	O
neurointerventional	B:C0184661
procedures	I:C0184661
.	O

Flow	B:C4049519
diversion	I:C4049519
using	O
the	O
pipeline	O
embolization	O
device	O
for	O
the	O
treatment	O
of	O
intracranial	O
aneurysms	I:C0007766
necessitates	O
the	O
use	O
of	O
dual	O
antiplatelet	I:C1096021
therapy	I:C1096021
to	O
reduce	O
this	O
risk	O
.	O

Flow	O
diversion	I:C4049519
using	O
the	O
pipeline	O
embolization	O
device	O
for	O
the	O
treatment	B:C0087111
of	O
intracranial	O
aneurysms	I:C0007766
necessitates	O
the	O
use	O
of	O
dual	O
antiplatelet	I:C1096021
therapy	I:C1096021
to	O
reduce	O
this	O
risk	O
.	O

Flow	O
diversion	I:C4049519
using	O
the	O
pipeline	O
embolization	O
device	O
for	O
the	O
treatment	O
of	O
intracranial	B:C0007766
aneurysms	I:C0007766
necessitates	O
the	O
use	O
of	O
dual	O
antiplatelet	I:C1096021
therapy	I:C1096021
to	O
reduce	O
this	O
risk	O
.	O

Flow	O
diversion	I:C4049519
using	O
the	O
pipeline	O
embolization	O
device	O
for	O
the	O
treatment	O
of	O
intracranial	O
aneurysms	I:C0007766
necessitates	O
the	O
use	O
of	O
dual	B:C1096021
antiplatelet	I:C1096021
therapy	I:C1096021
to	O
reduce	O
this	O
risk	O
.	O

The	O
use	O
of	O
platelet	B:C0032184
function	I:C0032184
testing	I:C0032184
before	O
pipeline	O
embolization	O
device	O
placement	O
remains	O
controversial	O
.	O

The	O
use	O
of	O
platelet	O
function	I:C0032184
testing	I:C0032184
before	O
pipeline	O
embolization	O
device	O
placement	B:C1533810
remains	O
controversial	O
.	O

A	O
retrospective	B:C0035363
review	I:C0035363
of	O
prospectively	O
maintained	O
databases	O
at	O
3	O
academic	O
institutions	O
was	O
performed	O
from	O
the	O
years	O
2009	O
to	O
2016	O
to	O
identify	O
patients	O
with	O
intracranial	O
aneurysms	I:C0007766
treated	O
with	I:C0332293
pipeline	O
embolization	O
device	O
placement	O
.	O

A	O
retrospective	O
review	I:C0035363
of	O
prospectively	O
maintained	O
databases	B:C0242356
at	O
3	O
academic	O
institutions	O
was	O
performed	O
from	O
the	O
years	O
2009	O
to	O
2016	O
to	O
identify	O
patients	O
with	O
intracranial	O
aneurysms	I:C0007766
treated	O
with	I:C0332293
pipeline	O
embolization	O
device	O
placement	O
.	O

A	O
retrospective	O
review	I:C0035363
of	O
prospectively	O
maintained	O
databases	O
at	O
3	O
academic	O
institutions	O
was	O
performed	O
from	O
the	O
years	O
2009	O
to	O
2016	O
to	O
identify	O
patients	O
with	O
intracranial	B:C0007766
aneurysms	I:C0007766
treated	O
with	I:C0332293
pipeline	O
embolization	O
device	O
placement	O
.	O

A	O
retrospective	O
review	I:C0035363
of	O
prospectively	O
maintained	O
databases	O
at	O
3	O
academic	O
institutions	O
was	O
performed	O
from	O
the	O
years	O
2009	O
to	O
2016	O
to	O
identify	O
patients	O
with	O
intracranial	O
aneurysms	I:C0007766
treated	B:C0332293
with	I:C0332293
pipeline	O
embolization	O
device	O
placement	O
.	O

A	O
retrospective	O
review	I:C0035363
of	O
prospectively	O
maintained	O
databases	O
at	O
3	O
academic	O
institutions	O
was	O
performed	O
from	O
the	O
years	O
2009	O
to	O
2016	O
to	O
identify	O
patients	O
with	O
intracranial	O
aneurysms	I:C0007766
treated	O
with	I:C0332293
pipeline	O
embolization	O
device	O
placement	B:C1533810
.	O

Clinical	B:C1516606
and	O
radiographic	O
data	O
were	O
analyzed	O
with	O
emphasis	O
on	O
thromboembolic	O
complications	O
and	O
clopidogrel	O
responsiveness	I:C3894555
.	O

Clinical	O
and	O
radiographic	O
data	O
were	O
analyzed	B:C0936012
with	O
emphasis	O
on	O
thromboembolic	O
complications	O
and	O
clopidogrel	O
responsiveness	I:C3894555
.	O

Clinical	O
and	O
radiographic	O
data	O
were	O
analyzed	O
with	O
emphasis	O
on	O
thromboembolic	O
complications	B:C0009566
and	O
clopidogrel	O
responsiveness	I:C3894555
.	O

Clinical	O
and	O
radiographic	O
data	O
were	O
analyzed	O
with	O
emphasis	O
on	O
thromboembolic	O
complications	O
and	O
clopidogrel	B:C3894555
responsiveness	I:C3894555
.	O

A	O
total	O
of	O
402	O
patients	O
underwent	O
414	O
pipeline	O
embolization	O
device	O
procedures	O
for	O
the	O
treatment	B:C0087111
of	O
465	O
intracranial	O
aneurysms	I:C0007766
.	O

A	O
total	O
of	O
402	O
patients	O
underwent	O
414	O
pipeline	O
embolization	O
device	O
procedures	O
for	O
the	O
treatment	O
of	O
465	O
intracranial	B:C0007766
aneurysms	I:C0007766
.	O

Thromboembolic	O
complications	B:C0009566
were	O
encountered	O
in	O
9.2	O
%	O
of	O
procedures	O
and	O
were	O
symptomatic	O
in	O
5.6	O
%	O
.	O

Thromboembolic	O
complications	O
were	O
encountered	B:C0422301
in	O
9.2	O
%	O
of	O
procedures	O
and	O
were	O
symptomatic	O
in	O
5.6	O
%	O
.	O

Clopidogrel	B:C0070166
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
compared	O
with	O
clopidogrel	O
responders	O
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

Clopidogrel	O
nonresponders	B:C0243095
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
compared	O
with	O
clopidogrel	O
responders	O
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

Clopidogrel	O
nonresponders	O
experienced	B:C0237607
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
compared	O
with	O
clopidogrel	O
responders	O
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	B:C0009566
compared	O
with	O
clopidogrel	O
responders	O
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
compared	O
with	O
clopidogrel	B:C0070166
responders	O
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
compared	O
with	O
clopidogrel	O
responders	B:C0919876
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

This	O
risk	O
was	O
significantly	O
lower	O
in	O
nonresponders	B:C0243095
who	O
were	O
switched	O
to	O
ticagrelor	O
when	O
compared	O
with	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
(	O
2.7	O
%	O
versus	O
24.4	O
%	O
)	O
.	O

This	O
risk	O
was	O
significantly	O
lower	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	B:C1999375
when	O
compared	O
with	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
(	O
2.7	O
%	O
versus	O
24.4	O
%	O
)	O
.	O

This	O
risk	O
was	O
significantly	O
lower	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	O
when	O
compared	O
with	O
patients	O
who	O
remained	O
on	O
clopidogrel	B:C0070166
(	O
2.7	O
%	O
versus	O
24.4	O
%	O
)	O
.	O

In	O
patients	O
who	O
remained	O
on	O
clopidogrel	B:C0070166
,	O
the	O
rate	O
of	O
thromboembolic	O
complications	O
was	O
significantly	O
lower	O
in	O
those	O
who	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
when	O
compared	O
with	O
those	O
who	O
did	O
not	O
(	O
9.8	O
%	O
versus	O
51.9	O
%	O
)	O
.	O

In	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
,	O
the	O
rate	O
of	O
thromboembolic	O
complications	B:C0009566
was	O
significantly	O
lower	O
in	O
those	O
who	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
when	O
compared	O
with	O
those	O
who	O
did	O
not	O
(	O
9.8	O
%	O
versus	O
51.9	O
%	O
)	O
.	O

In	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
,	O
the	O
rate	O
of	O
thromboembolic	O
complications	O
was	O
significantly	O
lower	O
in	O
those	O
who	O
received	O
a	O
clopidogrel	B:C0070166
boost	O
within	O
24	O
hours	O
pre-procedure	O
when	O
compared	O
with	O
those	O
who	O
did	O
not	O
(	O
9.8	O
%	O
versus	O
51.9	O
%	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	O
of	O
hemorrhagic	O
complications	B:C0009566
between	O
groups	O
.	O

Clopidogrel	B:C0070166
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
when	O
compared	O
with	O
clopidogrel	O
responders	O
.	O

Clopidogrel	O
nonresponders	B:C0243095
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
when	O
compared	O
with	O
clopidogrel	O
responders	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	B:C0009566
when	O
compared	O
with	O
clopidogrel	O
responders	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
when	O
compared	O
with	O
clopidogrel	B:C0070166
responders	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
when	O
compared	O
with	O
clopidogrel	O
responders	B:C0919876
.	O

However	O
,	O
this	O
risk	O
seems	O
to	O
be	O
mitigated	O
in	O
nonresponders	B:C0243095
who	O
were	O
switched	O
to	O
ticagrelor	O
or	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
.	O

However	O
,	O
this	O
risk	O
seems	O
to	O
be	O
mitigated	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	B:C1999375
or	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
.	O

However	O
,	O
this	O
risk	O
seems	O
to	O
be	O
mitigated	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	O
or	O
received	O
a	O
clopidogrel	B:C0070166
boost	O
within	O
24	O
hours	O
pre-procedure	O
.	O

